Skip to main content

Detail

Tea Pemovska
Tea Pemovska, PhDSenior postdoctoral researcher

Department of Medicine I (Division of Hematology and Hemostaseology)
Position: Research Associate (Postdoc)

ORCID: 0000-0003-2951-4905
T +43 1 40400-73784
tea.pemovska@meduniwien.ac.at

Further Information

Keywords

Drug Combinations; Drug Discovery; Drug Screening Assays, Antitumor; Hematologic Neoplasms; High-Throughput Screening Assays; Individualized Medicine; Leukemia; Leukemia-Lymphoma, Adult T-Cell; Metabolism; Molecular Targeted Therapy; Signal Transduction; Systems Biology; Translational Medical Research

Research group(s)

  • Functional Precision Hematology Group
    Research Area: The lab undertakes basic, translation, and clinical research to advance and develop novel diagnostics and treatment modalities for patients with hematological malignancies.
    Members:

Research interests

I am a cancer biologist with a special interest in molecular mechanisms underlying cancer development and progression and how to utilize that information to identify novel therapeutic strategies. I am specialized in developing and running high-throughput drug screening of patient-derived cancer cells and associated data analysis. In addition, my work focuses on how to use drug sensitivity data to unravel disease biology and personalized therapy options for cancer patients as well as repositioning of existing anti-cancer drugs for other indications. My expertise is in translational cancer systems biology particularly hematology, drug screening, and identification of novel cancer cell vulnerabilities that can be exploited for effective treatment of patients. My current research interests focus on the identification and characterization of metabolic dependencies in hematological malignancies with compound libraries and understanding underlying disease progression mechanisms in rare hematological cancers such as T-PLL. 

Techniques, methods & infrastructure

High-throughput flow cytometry-based drug screening; single-cell RNA sequencing; working with patient samples from patients with hematological malignancies; drug libraries; functional precision medicine clinical trials

Selected publications

  1. Pemovska, T. et al., 2015. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature, 519(7541), pp.102–105. Available at: http://dx.doi.org/10.1038/nature14119.
  2. Pemovska, T. et al., 2013. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 3(12), pp.1416–1429. Available at: http://dx.doi.org/10.1158/2159-8290.CD-13-0350.
  3. Yadav, B. et al., 2014. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 4(1). Available at: http://dx.doi.org/10.1038/srep05193.
  4. Karjalainen, R. et al., 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML. Blood, 130(6), pp.789–802. Available at: http://dx.doi.org/10.1182/blood-2016-02-699363.
  5. Pemovska, T., Bigenzahn, J.W. & Superti-Furga, G., 2018. Recent advances in combinatorial drug screening and synergy scoring. Current Opinion in Pharmacology, 42, pp.102–110. Available at: http://dx.doi.org/10.1016/j.coph.2018.07.008.